Trials / Terminated
TerminatedNCT03717415
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rebastinib | Administered orally |
| DRUG | Carboplatin | Administered by IV infusion |
Timeline
- Start date
- 2019-01-02
- Primary completion
- 2022-05-01
- Completion
- 2022-11-01
- First posted
- 2018-10-24
- Last updated
- 2024-12-27
- Results posted
- 2024-12-27
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03717415. Inclusion in this directory is not an endorsement.